Gaps in knowledge and prospects for research of adjuvanted vaccines

Vaccine

Volumn 33, Issue S2, 2015, Pages B40-B43

  Seder, Robert ^a   Reed, Steven G ^b   O'Hagan, Derek ^c   Malyala, Padma ^c   D'Oro, Ugo ^d   Laera, Donatello ^d   Abrignani, Sergio ^e   Cerundolo, Vincenzo ^f   Steinman, Lawrence ^g   Bertholet, Sylvie ^d  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^c Novartis Vaccines Cambridge   (United States)

^d NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^e Instituto Nazionale Genetica Molecolare   (Italy)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant; Vaccine

Indexed keywords

CANCER VACCINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; PROTEIN; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VACCINE; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG FORMULATION; GERIATRIC PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOTHERAPY; INFECTION; INNATE IMMUNITY; MALARIA; MALIGNANT NEOPLASTIC DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; TUBERCULOSIS; DRUG DEVELOPMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; MEDICAL RESEARCH; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; BIOMEDICAL RESEARCH; DRUG DISCOVERY; HUMANS; VACCINES;

EID: 84929872790     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.057     Document Type: Review

References (14)

1. Ehreth Jenifer The global value of vaccination. Vaccine 2003, 21.7:596-600.
2. Harper Diane M., Franco Eduardo L., Wheeler Cosette, Ferris Daron G., Jenkins David, Schuind Anne, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364(9447):1757-1765.
3. Pizza Mariagrazia, Scarlato Vincenzo, Masignani Vega, Giuliani Marzia Monica, Arico Beatrice, Comanducci Maurizio, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287(5459):1816-1820.
4. Riedel Stefan Edward Jenner and the history of smallpox and vaccination. Proc (Baylor Univ, Med Center) 2005, 18(1):21.
5. Rappuoli Rino, Black Steven, Lambert Paul Henri Vaccine discovery and translation of new vaccine technology. Lancet 2011, 378(9788):360-368.
6. Cox John C., Coulter Alan R. Adjuvants-a classification and review of their modes of action. Vaccine 1997, 15(3):248-256.
7. Podda Audino The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001, 19(17):2673-2680.
8. ®). Drugs 2011, 71(4):465-488.
9. ® adjuvant and RC529, are efficient adjuvants for CD4+ T cells. J Leukoc Biol 2005, 78(6):1273-1280.
10. Pantel Austin, Cheong Cheolho, Dandamudi Durga, Shrestha Elina, Mehandru Saurabh, Brane Luke, et al. A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo. Eur J Immunol 2012, 42(1):101-109.
11. Levitz Stuart M., Golenbock Douglas T. Beyond empiricism: informing vaccine development through innate immunity research. Cell 2012, 148(6):1284-1292.
12. Alonso Pedro L., Sacarlal Jahit, Aponte John J., Leach Amanda, Macete Eusebio, Milman Jessica, et al. Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004, 364(9443):1411-1420.
13. Nordly Pernille, Rose Fabrice, Christensen Dennis, Nielsen Hanne Mørck, Andersen Peter, Agger Else Marie, et al. Immunity by formulation design: induction of high CD8+ T-cell responses by poly (I:C) incorporated into the CAF01 adjuvant via a double emulsion method. J Control Release 2011, 150(3):307-317.
14. O'Hagan Derek T., Singh Manmohan, Ulmer Jeffrey B. Microparticle-based technologies for vaccines. Methods 2006, 40(1):10-19.